

Speed Dating with your UroGyne: Advances in Prolapse Management

39th Annual Contemporary Issues in Obstetrics and Gynecology
Sandestin, Florida
July 21, 2025

Tanaz Ferzandi, MD, MBA, MA
President, American Urogynecologic Society
Vice Chief of Staff, Keck Hospital of USC
Service Line Chief of Obstetrics & Gynecology, Keck Hospital of USC
Director, Division of Urogynecology and Reconstructive Pelvic Surgery
Associate Professor of Obstetrics and Gynecology

DISCLOSURES

- Juniper BioMedical - Medical Advisory Board
 - Aqua Therapeutics - Scientific Advisory Board
 - Origyn Solutions - Clinical Advisory Board
 - Esch Holdings, LLC – Consultant
 - FemTherapeutics – Consultant
-
- ABOG - General Gyn and Urogynecology board examiner; travel honoraria
 - Defense Expert Witness for Medical Malpractice (General Gyn and Urogyne)

OBJECTIVES

1. Discuss definition and prevalence of prolapse
2. Understand basic patient selection and options
3. Know the available non-surgical and surgical options
 - a. When to refer
 - b. Complications of procedures

PELVIC ORGAN PROLAPSE (POP)


- Definition: POP is the descent of one or more aspects of the vagina and uterus: the anterior vaginal wall, posterior vaginal wall, the uterus (cervix), or the apex of the vagina (post hysterectomy).
 - affects an estimated 3.3 million women, with projected 46% increase by 2050
- Per the WHI – prevalence of POP is ~40%
- Peak incidence of symptoms in women aged 70-79 years. However, most women remain asymptomatic
- Prevalence across all ages is 3-6% when defined by symptoms
 - Up to 50% when defined by vaginal exam
 - In one review, the prevalence of POP based on reported symptoms was much lower (3–6%) than the prevalence identified by examination (41–50%)
- Lifetime risk of having at least one surgery for POP by age 80 is 11.1%
 - US women have a 13% lifetime risk of undergoing surgery for POP
 - Approximately 300K surgeries for POP are performed annually (2010 data)

RISK FACTORS for POP


Obstetric Risk Factors	Non-Obstetric Risk Factors
Vaginal parity	Shape and orientation of bony pelvis
Advancing age	Family history of POP
Obesity	Age/menopause
Pregnancy (regardless of mode of delivery)	Race/ethnic origin
Forceps-asst delivery	Heavy lifting (career or exercise related)
Young age at first delivery	Chronic constipation
Prolonged 2 nd stage of labor	Previous hysterectomy/pelvic surgery
Infant birthweight > 4500g	Smoking
	Chronic illnesses that result in constant stress and strain on the pelvic floor
	Genetic factors, such as connective tissue weakness (hypermobility), and genetic collagen deficiency disorders (Marfan syndrome, Ehlers–Danlos syndrome)

LEVELS OF SUPPORT



- Apical
 - Uterine / Vaginal Vault
- Anterior Vaginal Compartment
 - Cystocele
- Posterior Vaginal Compartment
 - Rectocele
- Perineal Deficiency
- Procidentia
- Rectal Prolapse



LANGUAGE MATTERS



POP-Q



Is POP-Q II Now Overdue?

Urogynecology 2025;31:71-73
DOI: 10.1097/SPV.0000000000001650

The POP-Q system to evaluate prolapse was published 28 years ago, and it is time to consider POP-Q II. Staging systems for cancer or endometriosis are revised and improved over time as new data become available to improve their ability to predict outcomes and target treatment.¹ Changes can be important and substantive. For example, in breast cancer staging, the addition of biomarkers (estrogen and progesterone receptor and HER2 status) was added to the traditional TNM system because these biomarkers add significant prognostic information and drive therapy decisions.

Three areas should be considered when improving the POP-Q system. First, POP-Q stage definitions are not evidence-based and do not conform to the internationally recognized definition of prolapse, or to what the public understands about disease stages. Second, urogenital hiatus size is now clearly established as a factor influencing both surgical outcome and prolapse development after birth, yet it is not currently used in assigning stages. Third, the way in which the POP-Q examination is conducted is not standardized.

John O. L. DeLancey, MD
From the Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI.
Correspondence: John O. L. DeLancey, MD.
E-mail: delancey@med.umich.edu.
The author has declared that there are no conflicts of interest.

© 2025 American Urogynecologic Society.
All rights reserved.

ACOG PRACTICE BULLETIN No. 185



The American College of
Obstetricians and Gynecologists
WOMEN'S HEALTH CARE PHYSICIANS



AUGS
Advancing Female Pelvic Medicine
and Reconstructive Surgery

INTERIM UPDATE

ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

NUMBER 185, NOVEMBER 2017 *(Replaces Practice Bulletin Number 176, April 2017)*

Committee on Practice Bulletins—Gynecology and American Urogynecologic Society. This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology and the American Urogynecologic Society in collaboration with Paul Tulikangas, MD.

INTERIM UPDATE: This Practice Bulletin is updated as highlighted to reflect recent systematic review evidence on the use of biologic and synthetic mesh grafts in the repair of anterior pelvic organ prolapse.

Pelvic Organ Prolapse

Pelvic organ prolapse (POP) is a common, benign condition in women. For many women it can cause vaginal bulge and pressure, voiding dysfunction, defecatory dysfunction, and sexual dysfunction, which may adversely affect quality of life. Women in the United States have a 13% lifetime risk of undergoing surgery for POP (1). Although POP can occur in younger women, the peak incidence of POP symptoms is in women aged 70–79 years (2). Given the

DECISION TREE

- Expectant Management
 - Patient's desires (aversion to surgery)
 - Pelvic Floor Muscle Training
 - Bladder emptying
 - UTIs
 - Vaginal atrophy, erosions
- Pessary
 - Patient's desires (aversion to surgery)
 - Sexual Activity
 - Dexterity
 - *Dependability* for routine exams
- Surgery
 - Overall health, time off work, type of job (exertion), etc

PESSARY



MILEX Products, Inc., Chicago, IL, USA

- A. Ring
- B. Shaatz
- C. Gellhorn
- D. Gellhorn
- E. Ring with support
- F. Gellhorn
- G. Risser
- H. Smith
- I. Tandem cube

- J. Cube
- K. Hodge with knob
- L. Hodge
- M. Gehrung
- N. Incontinence dish with support
- O. Donut
- P. Incontinence ring
- Q. Hodge with support
- R. Inflatoball (latex)

CONTRAINDICATIONS

- Chronic vaginal irritation
- Erosions or ulcerations
- Active infections / PID
- Sexually active women who cannot remove/reinsert device
- Marked vaginal atrophy
- Exposed foreign body (i.e. vaginal mesh, or prior procedure)
- Non-compliance or unable to present for periodic examinations
- Allergy to product / latex allergy

CAUTION WITH ...

- Short vaginal length, $< 6\text{cm}$
- Wide vaginal introitus, ≥ 4 fingerbreadths
- Genital hiatus/total vaginal length ratio > 0.8
- Lower POPQ stage
- Prior hysterectomy
- Prior POP surgery
- Higher BMI
- Presence of SUI
- (distal prolapse – ant/post)*




Vaginal Pessary Use and Management for Pelvic Organ Prolapse

Developed by the joint writing group of the American Urogynecologic Society and the Society of Urologic Nurses and Associates. Individual writing group members are noted in the Acknowledgments section.

TIPS and TRICKS & COMPLICATIONS




Most women can be managed with 2.5", 2.75" and 3"





Gellhorn – SS and LS

Most women can be managed with the 2.5, 2.75, and 3” sizes



Try Plastic Wrap to Improve Estrogen Delivery

BY SHARON WORCESTER
Southeast Bureau

ATLANTA — Occlusion with plastic wrap may improve the delivery of topical estrogen to the vaginal area in postmenopausal women with vaginal atrophy who are being prepared for pelvic reconstructive or obliterative surgery, Peter L. Rosenblatt, M.D., said at the annual meeting of the American Urogynecologic Society.

It is generally accepted that local estrogen therapy improves vaginal thickness and integrity of the vagina in this population, and most surgeons typically recommend several months of treatment before pelvic reconstructive surgery, explained Dr. Rosenblatt of Harvard Med-

ical School, Boston. But patients with advanced prolapse, who can have particularly poor tissue quality, are likely to have problems with the cream rubbing off on pads or undergarments. Pessaries can help, but some patients can't retain them due to poor perineal support, and in some cases they can cause or worsen erosions.

To keep the estrogen cream in place, Dr. Rosenblatt borrowed the plastic wrap occlusion technique from dermatologists, who often use plastic wrap with the ap-

plication of EMLA cream before laser hair removal, skin biopsies, and other procedures.

Have the patient apply a thick layer of estrogen cream and cover it with plastic wrap or any other occlusive dressing, he advised.

"We have the patient use this every other night for several hours. ... It's not pretty, but it gets the job done," he said at the meeting.

In his "informal experience" with eight

patients who were candidates for pelvic surgery, subjective improvement in tissue quality, including resolution of erosions in one patient, was noted in all except two patients. Those patients both had a prolapse that would recede when they weren't bearing down, which would displace the plastic wrap.

A prospective trial comparing the effects of standard estrogen cream application and estrogen cream application plus plastic wrap is planned, Dr. Rosenblatt said. ■



Plastic wrap is applied as occlusive dressing over estrogen cream.

COURTESY DR. PETER L. ROSENBLATT




COOL COMFORT

Stop Warts Cold
with Histofreezer® Portable Cryosurgical System

RESOLVE GENITAL WARTS
THE MORE COMFORTABLE WAY



THE WELL TOLERATED WAY TO REMOVE WARTS

MY BIAS ...







NEGLECT HAS ITS CONSEQUENCES





PESSARIES ON THE HORIZON



REIMBURSEMENT

CPT	Description	Total RVU Non-facility	Total RVU Facility
57160	Fitting and insertion of pessary or other intra-vaginal support device (initial, re-fitting)	2.15	1.33
57150	Irrigation of vagina and/or application of medicament for treatment of bacterial, parasitic or fungoid disease	1.27	0.82
A4561	Pessary, rubber	0	0
A4562	Pessary, non-rubber	0	0
A4320	Irrigation tray with bulb or piston syringe, any purpose	0	0

E/M Code with 25 Modifier if appropriate
Follow-up visits – only use E/M code (do not rebill 57160)

PELVIC FLOOR PHYSICAL THERAPY

- Investigate the effectiveness of pelvic floor muscle training in reversing pelvic organ prolapse and alleviating symptoms.
- Assessor-blinded, parallel group, randomized, controlled trial
- 59 in PT group, 50 in control; POP I–III (only 22% had Stage III)
- Each woman was individually supervised by a PT once a week during the first 3 months and every second week during the last 3 months
- RESULTS: Eleven (19%) women in the PT improved 1 POPQ Stage vs. 4 (8%) controls (P .035).

VAGINAL CONES



- Evaluated the effectiveness of using a specific type of vaginal cone in perineal rehabilitation
- 54 patients with a mean age of 39.68 years $\pm$ 3.34 with PFDs; 3 months
- Impact of the intervention on quality of life: a significant decrease in bladder and urinary problems (UIQ-7) and a non-significant decrease in vagina or pelvis problems (POPIQ-7)

- Systematic Review:
- Extracted reports range from 2000 to 2020; all were randomized controlled trials
- The sample size included ranged from 40 to 250 in number
- Vaginal cone training significantly improved pelvic floor muscle function and quality of life
- Pronounced impact on urinary symptoms but minimal effect on pelvic organ prolapse symptoms



LASER THERAPY??

- Aim: Er:YAG laser for managing ant/post prolapse
- Single blind, 1:1 trial; POP II-III
 - 30 women; 3 treatments at monthly intervals vs. no tx
 - 0% in either group had POPQ Stage 0 at 1 or 4 mos
 - PGI-I, 2/15 (14%) and 0/15 (0%) participants declared much better/very much better in the laser and watchful-waiting group, respectively.
- No support for use of Er:YAG for treatment of ant/port vaginal wall

Randomized Controlled Trial > [Climacteric](#). 2021 Feb;24(1):101-106.
doi: 10.1080/13697137.2020.1789092. Epub 2020 Jul 28.

Can pelvic organ prolapse in postmenopausal women be treated with laser therapy?

S Athanasiou ¹, E Pitsouni ¹, L Cardozo ², D Zacharakis ¹, E Petrakis ¹, D Loutradis ³, T Grigoriadis ¹

LASER AND POP



- Compare the efficacy of Er:YAG laser for mild to moderate POP to that of PFE
- Design: Single center randomized controlled trial
- 46 women with mild to moderate prolapse were enrolled (23 in each group)
 - Vaginal laser treatment (3–6 applications) vs PFE (9–18 sessions)
 - Subjective change in prolapse symptoms at 4 mos, Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6)
- Results: The mean difference in POPDI-6 scores at 4 months was 1.09 (95 %CI= 6.02;8.12), showing non- inferiority of laser to PFE (p = 0.004).
- At 24 months, 50 % (11/22) of laser-patients and 43 % (9/21) of PFE-patients requested additional, yet alternative treatment

This document comments:

» 10.1111/1471-0528.16273

Editorial Comment: Laser therapy for urinary incontinence and pelvic organ prolapse: a systematic review

Authorship

SCIMAGO INSTITUTIONS RANKINGS

» Text

» References

» Publication dates

K Mackova^{1,2}, L Van Daele³, A-S Page⁴, I Geraerts^{5,6}, L Krofta², J Deprest^{1,4}

BJOG. 2020 Oct;127(11):1338-1346.

COMMENT

This paper's objective was to present a systematic review on the use of LASER therapy for the treatment of urinary incontinence (UI) and pelvic organ prolapse (POP). Erbium (ER-YAG) and carbon dioxide (CO₂) lasers were introduced as a new non-invasive treatment in gynecology, initially for the so-called menorrhagia syndrome, and at a later date also being considered as a treatment option for UI and POP. The authors selected 31 studies involving 1530 patients in accordance with the PRISMA-guideline. The studies included ER-YAG (n = 21), CO₂ (n = 9) LASERs, or both. A single RCT was included, in which the turned to the vagina, as sham group (¹), and two studies were controlled cohort series.

All studies reported significant improvement both for objective and validated subjective symptoms. Three studies addressed urge incontinence as a primary endpoint. POP was a primary endpoint in which reported anatomical improvements to grade 0 or 1 in 85% of the subjects and to grade 0 or 1 in five LASER therapy sessions. Lower cystocele grades were associated with a higher success rate. However, the results of the data did not allow for the development of a meta-analysis. The authors concluded that although short term results of LASER therapy for UI and POP seem beneficial, current information on long term results, cost-effectiveness compared to well-established surgical treatments and even about which LASER model to use are lacking.

This systematic review stands out due to its high scientific standards and by being the first to include the controversial topic of LASER use in POP treatment. Be that as it may, we must highlight that the quality of the majority of the studies included is still poor, both in terms of sample sizes and also follow-up. In addition, as the physical characteristics of ER-YAG and CO₂ LASERs are quite different, conclusions on the effectiveness and adverse effects of these therapies is still very limited.

REFERENCES

- 1 Blaganje M, Šćepanovic D, Žgur L, Verdenik I, Pajk F, Lukanovic A. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2018;224:153-8.
- 2 Ogrinc UB, Sencar S. Non-ablative vaginal erbium YAG laser for the treatment of cystocele. Ital J Gynaecol Obstet. 2017;29:19-25.

Editorial Comment: Laser therapy for urinary incontinence and pelvic organ prolapse: a systematic review

Authorship

SCIMAGO INSTITUTIONS RANKINGS

K Mackova^{1,2}, L Van Daele³, A-S Page⁴, I Geraerts^{5,6}, L Krofta², J Deprest^{1,4}

BJOG. 2020 Oct;127(11):1338-1346.

EBCOG – LASER AND POP

- EBCOG recommends that laser device manufacturers should provide evidence about long-term data on safety and effectiveness of their own devices. We would recommend further good quality research targeting specific cohort of patients, standardizing treatment regimens and using appropriate patient reported outcome measures.

Contents lists available at [ScienceDirect](#)

 **ELSEVIER**

European Journal of Obstetrics & Gynecology and Reproductive Biology

journal homepage: www.journals.elsevier.com/european-journal-of-obstetrics-and-gynecology-and-reproductive-biology


Full length article

European Board and College of Obstetrics and Gynaecology (EBCOG) position statement on the use of laser vaginal devices for treatment of genitourinary syndrome of menopause, vaginal laxity, pelvic organ prolapse and stress urinary incontinence

Ilias Giarenis^a, Sofia Tsiapakidou^b, Martino Zacche^c, Sambit Mukhopadhyay^{a,d,*}, Tahir Mahmood^e



“The majority of cases of prolapse of the vagina can be successfully operated upon via the vagina.
The cure is not infrequently difficult, and a great deal of surgical ingenuity is required.”
Richard W. TeLinde



KEEP IT SIMPLE

- Apical

(Laparoscopy, Robot Assisted, Vaginal, Abdominal)

- Sacrocolpopexy (post hysterectomy) with mesh
- SCH with Sacrocervicopexy with mesh
- Sacrohysteropexy
- Uterosacral ligament suspension (uterine or vault)
- Sacrospinous fixation, +/- vaginal hysterectomy
- Sacrospinous Hysteropexy
- Iliococcygeal Vaginal Suspension
- [Rectopexy]

KEEP IT SIMPLE

- **Anterior Compartment +/- Graft or Mesh**
 - Anterior Colporrhaphy
 - Para vaginal Defect Repair (vaginal, abdominal)
- **Posterior Compartment +/- Graft or Mesh**
 - Posterior Colporrhaphy – levator plication
 - Posterior Colporrhaphy – site specific
 - Sacrospinous Ligament Fixation
- **Obliterative**
 - Le Fort Colpocleisis (or “colpectomy”)
 - +/- hysterectomy

Sacrocolpopexy

- First described in 1962, Dr. Frederick Lane
- Grade A: SCxP preferred for vaginal apical prolapse
- Grade B: monofilament polypropylene mesh preferred graft
- Grade B: LSC is preferred technique
- Grade C: either permanent or delayed abs sutures @ vagina
- Grade C: permanent sutures or tackers @ sacral promontory
- Grade C: closing peritoneum over mesh
- Insufficient evidence/conflicting data on total vs. SCH
- Insufficient evidence/conflicting data for uterine preservation
 - Nevertheless, uterus preservation is associated with less mesh erosion (Grade B)

Repair of Posthysterectomy Vaginal-Vault Prolapse

FREDERICK E. LANE, M.D., F.A.C.O.G.

UNTIL RECENTLY, prolapse of the vaginal vault following total hysterectomy was infrequently encountered in gynecologic practice. In fact, Phaneuf, reporting on 5554 gynecologic operations performed from 1936 to 1951, found that only 38 were for prolapse following hysterectomy. Of this number, 31 operations were for prolapse of a cervical stump and 7, for prolapse of the vaginal vault. However, an increase in the number of vaginal hysterectomies now performed to correct prolapse appears to have resulted in a greater frequency of vaginal-vault prolapse.

While the statistics concerning the incidence of this complication following total abdominal and vaginal hysterectomy have not been accurately formulated, a review of the current literature reveals many reports of the occurrence of this condition. Symmonds and Pratt presented a study of 69 cases in which vaginal prolapse had occurred in 37 after vaginal hysterectomy, and in 32 following total abdominal hysterectomy. Embrey noted a 6 per cent incidence of postoperative enterocele after vaginal hysterectomy, and Waters reported 14 recurrences of cystocele, enterocele, and/or vault prolapse in a group of 210 vaginal hysterectomies.

The author expresses appreciation to Dwight A. Callagan, Capt. (MC), USN, for his work in the development of the technic of stapling the synthetic to the sacrum.

Submitted for publication Aug. 9, 1961.


Backer and Kristoffersen discovered prolapse in 43 per cent of 90 patients followed from 1 to 2½ years after vaginal hysterectomy. Subjective complaints were recorded in 28 per cent, while 14 patients required reoperation. Among the factors they held responsible for unsatisfactory postoperative results was the improper selection of candidates for operation. Patients with preoperative prolapse seemed less likely to experience success.

In most patients with prolapse, inherent anatomic weakness and pregnancy appear to be basic factors in the development of the lesion. Because of its tenuous nature, the endopelvic fascia is limited in supportive ability; moreover, the facts that the uterosacral ligaments are widely spread in their attachment to the posterior vaginal vault and that the musculofascial envelopes of pelvic structures may be overstretched by pregnancy also contribute to this condition. Prolapse of the vaginal vault may occur as a primary entity or as the result of an enterocele unrecognized at hysterectomy or a recurrent cystocele. Although prolapse is most commonly found in women of the older age group, it may also be seen in younger women. It is often observed after supravaginal hysterectomy because of the failure to apply correctly major supports to the pelvic structures and the vaginal vault.


Numerous procedures have been described for correction of the prolapsed vagi-

Sacrocolpopexy with Mesh – the ‘gold standard’


Sacrohysteropexy (uterus in place)




Sacrocolpopexy (post hysterectomy)



Sacrocolpexy



THE “GOLD STANDARD”



Sacrocolpopexy – complications (specific)

- Hemorrhage (presacral vessels)
 - blood transfusions
- Mesh exposure/erosion
 - SCH vs Total
- Bladder injury
- Ureteral injury
- Bowel obstruction
 - reperitonealization of mesh
- Spondylodiscitis
- Other
 - wound complications
 - trocar related injuries

Lumbar spondylodiscitis

- 36.5% laparotomy
- 44.2% laparoscopic
- 15.4% robotic-assisted
- 63.5% cases - Sacral anchorage was performed with synthetic mesh (nonabsorbable or partially absorbable)
- Biologic mesh 1.9%, direct sutures 3.8%
 - 25% of all cases, the type of sacral anchorage was not specified.
- The attachment to the promontory
 - was made with sutures in 36.5% (all nonabsorbable sutures)
 - staples, clips, tacks or screws in 23% of the cases
 - information lacking in 40.4% of the cases

Delayed Complication: Lumbar spondylodiscitis



Figure 1. MRI: Lumbar pyogenic spondylodiscitis, enhancement of soft tissues surrounding the L5-S1 vertebrae (arrow). MRI = magnetic resonance imaging.




Figure 2. MRI after mesh removal 2 wk later: bony destruction of the lower part of the L5 vertebra and the dome of the sacrum (arrow). MRI = magnetic resonance imaging.

Sacrospinous Ligament Fixation (SSLF)

- Sederl 1958; Richter 1968; Randall and Nichols 1971
- Transvaginal surgical treatment is mainly represented by the sacrospinous ligament fixation
- Sutures the posterior vaginal wall to the sacrospinous ligament
- Compared to sacrocolpopexy, the SSLF
 - avoids abdomen
 - lower morbidity
 - shorter operation / anesthesia time / LOS
 - faster postoperative recovery
 - lower cost
- higher rate of dyspareunia
- higher rate of recurrence

Sacrospinous Ligament Fixation

Unilateral/ Bilateral







Fig. 6: Anatomy of sacrospinous ligament






Coloplast®

Key landmarks (SSLF)

- Ischial Spine
- Sacrospinous ligament (SSL)
- Pudendal vessels and nerves
- Sciatic nerve
- Inferior Gluteal arteries and nerves






Complications (specific)

- Gluteal pain – requiring removal of stitch(es)
- Bleeding – can be catastrophic, inaccessible
- Injury to rectum (ureter, bladder)
- Constipation
- UTI
- Dyspareunia
- Myositis
- Perineal necrotizing infection of the gluteal region

Uterine preservation or not? SSF Hysteropexy

- recurrence rate was 19.5%
- retreatment rate was 11.0%
 - cystocele was the most common recurrent compartment (17.1%)
 - the uterine preservation group (n = 66) was younger, had lower parity, and had fewer stage 3 to 4 cystoceles and uterine prolapses than the concomitant hysterectomy group (n = 16)
 - Shorter operation times (99.4 minutes vs 153.7 minutes, $P = .002$) and lower anatomical recurrence rates (11.5% vs 45.5%, $P = .039$) were found in the uterine preservation group before and after PSM(propensity score matching).
 - Previous pelvic organ prolapse surgery (hazard ratio 3.14) and concomitant hysterectomy (hazard ratio 4.08) were identified as risk factors for anatomical recurrence
 - most common adverse event was buttock pain (14.6%); resolved spontaneously within 4 weeks
- compared with concomitant hysterectomy, SSLF with uterine preservation reduces the anatomical recurrence rate.


High Uterosacral Ligament Suspension +/- VH



JB, 48yo



LSC – uterosacral ligament plication





Uterine preservation or not? SSF vs. USLS

- 4 sites, 147 patients underwent SSHP and 114 underwent USHP
 - SSHP patients were younger, higher BMI
- One year postop: 1 in 3 patients were available for follow-up
 - no differences in prolapse recurrence between patients who underwent USHP versus SSHP
 - adverse events were low and less than 5% of patients underwent subsequent hysterectomy for prolapse
 - There were 10 (3.8%) anatomic failures: 3 (2%) SSHP and 7 (6.1%) USHP ($p=0.109$)
 - Some pts had trachelectomy
 - Variety of suture techniques


LeFort Colpocleisis

- 1823 - Gerardin described obliterative vaginal surgery in elderly women who are no longer sexually active.
- 1877 – Leon Le Fort performed and published the technique for the procedure now known as Le Fort partial colpocleisis
- Elderly
- High risk for prolonged, abdominal or reconstructive procedure
- **Vaginal Penetration**









Paravaginal Repair (Abdominally / LSC)



Vaginal Colporrhy



2008 → 2011 ... and beyond




Mesh

Why??

- Success rates for native repairs

Surgical mesh materials can be divided into four general categories:

- **non-absorbable synthetic (e.g., polypropylene or polyester)**
- absorbable synthetic (e.g., poly(lactic-co-glycolic acid) or poly(caprolactone))
- biologic (e.g., acellular collagen derived from bovine or porcine sources)
- composite (i.e., a combination of any of the previous three categories)



Blame Game

510(k) process

Surgeons/Consultants

Device Manufacturers / DTC Marketing






Present state:

522 Studies - The FDA has ordered manufacturers to conduct post-market surveillance studies to address specific safety concerns related to mini-sling devices for stress urinary incontinence (SUI) and surgical mesh used for transvaginal POP repair.

Device Reclassification - In 2016, the FDA reclassified urogynecologic surgical mesh for transvaginal POP repair from class II (moderate risk) to class III (high risk), requiring premarket approval applications for new devices.

Where do we go from here?



THANK YOU



World Health Organization

“Health is a state of complete physical, mental, and social well-being,
not merely the absence of disease or infirmity.”

ferzandi@usc.edu

www.augs.org

www.acog.org

www.iuga.org

Boston Garden, 2019



PCH, 2021



“It’s better to be tormented by doubts, rather than run the risk of lying in the wrong conviction”

Alessandro Manzoni